Deprescribing Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF)

• Status: NOT_YET_RECRUITING
• Trial end date: 2029-04-01

Summary

The goal of this study is to learn whether stopping beta-blockers can help older adults with heart failure with preserved ejection fraction (HFpEF) feel better and function better. This study will test whether "deprescribing" or stopping these medications in a careful, guided way can improve symptoms and quality of life.

Participants will be randomly assigned to one of two groups:

Deprescribing group: Beta-blockers are gradually reduced using capsules that contain decreasing doses.

Usual care group: Beta-blockers are continued at the usual dose in look-alike capsules.

All participants will:

• Take study medicine for about 4 months
• Have their blood pressure and heart rate monitored
• Complete regular phone calls and questionnaires about how they are feeling

This study does not involve any experimental medication. Participants active involvement in the study will last approximately 4 months. During these 4 months they will have 8 scheduled telephone visits.

• Phase: PHASE4

Details

• Lead Sponsor: Weill Medical College of Cornell University
• Collaborators: Kaiser Foundation Research Institute; National Institute on Aging (NIA)
• Treatments: Adrenergic beta-Antagonists; Atenolol; Bisoprolol; Carvedilol; Deprescriptions; Metoprolol